secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001493152-25-019095
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency
--------------------------------------------------------------------------------

- Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.
- Nasdaq notified company on Oct 22 of bid-price non-compliance (closing price <$1 for 30 days); no grace period due to prior reverse split.
- Company received $2.2M gross from warrant exercises in September to raise stockholders' equity above $2.5M minimum.
- Company intends to request a hearing to appeal delisting; no assurance of continued listing.
- Warrants issued in the inducement become exercisable only after stockholder approval per Nasdaq Rule 5635(d).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315225019095/0001493152-25-019095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315225019095/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer